Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Intravenous (IV) Therapy and Vein Access Market by Type (Implantable Ports, Intravenous Catheters, Hypodermic Needles, Infusion Pumps, Other), by Medical Application (Volume Expander, Medication Administration, Blood Based Products, Nutrition And Buffer Solution), by End User (Hospitals, Ambulatory Surgical Center, Clinics): Global Opportunity Analysis and Industry Forecast, 2020-2030

A02019

Pages: 214

Charts: 61

Tables: 152

The global Intravenous Therapy and Vein Access Market size was valued at $22.8 billion in 2020 and is projected to reach $37.5 billion by 2030, growing at a CAGR of 5.1% from 2021 to 2030. Intravenous (IV) therapy is the process of infusion of liquid substances such as electrolytes, medicines, nutrition, and blood-based products directly into the veins as a therapeutic treatment. IV therapy-based treatment is the fastest way of delivering fluids to different parts of the body. This treatment is used for diseases, including heart attack, stroke, and poisoning. The patient in such cases should receive medication at the earliest, and hence IV medication is prescribed. Therefore, some of the drugs prescribed intravenously include chemotherapy drugs antibiotics, antifungal drugs, pain medications, immunoglobulin medication, and drugs for low blood pressure. IV therapy works fast, is easy to monitor, and prevents side effects to the gastrointestinal system. provides quick immune system response and relief from chronic diseases compared to the oral mode of medication. can be easily monitored and comprises an infusion pump that controls the volume of a substance to be administered in the body.

[COVIDIMPACTSTATEMENT]

 

The Intravenous Therapy and Vein Access Market trends include a rise in the incidence of chronic diseases, growth in road accidents, and a surge in trauma cases. In addition, an increase in healthcare expenditure and healthcare insurance are expected to fuel the Intravenous Therapy and Vein Access Market growth during the forecast period. However, the lack of experienced healthcare professionals restricts the market growth. Conversely, the rise in critical care therapies and the increase in the geriatric population are the key factors that provide Intravenous Therapy and Vein Access Market opportunity.

Furthermore, an increase in the number of approved IV drugs that are used for therapy drives the growth of the market. For instance, according to the journal of New England Journal of Medicine (NEJM), the Artesunate injection was approved by Food and Drug Administration (FDA) in June 2020 for the treatment of malaria.

The Intravenous Therapy and Vein Access Market is segmented on the basis of type, medical application, and region. Depending on the type, the market is classified into implantable ports, IV catheters, hypodermic needles, infusion pumps, and others. According to medical application, the market is categorized into volume expanders, medication administration, blood-based products, and nutrition & buffer solutions. As per end-user, the market is fragmented into hospitals, ambulatory surgical centers, and clinics. Region-wise, the Intravenous Therapy and Vein Access Market analysis is done across North America, Europe, Asia-Pacific, and LAMEA.

By Type Segment Review

[TYPEGRAPH]

According to type, the Vein Access Industry market is classified into implantable ports, IV catheters, hypodermic needles, infusion pumps, and others. The IV catheters are the fastest growing product segment. The growth of the IV catheter market is fueled by rising in the use of IV catheters during surgical procedures for IV therapies and during the transfer of blood, medicine, and other nutrients to different parts of the body are the key factors driving the growth of the market.

By Medical Application Segment Review

[MEDICALAPPLICATIONGRAPH]

According to medical applications, the Intravenous Therapy and Vein Access Market market is classified into volume expanders, medication administration, blood-based products, and nutrition & buffer solutions. The medication administration segment held the highest market share, owing to the high usage of IV therapy for transferring medicines for diseases such as diabetes, and cancer.

By End-User Segment Review

[ENDUSERGRAPH]

As per end-user, the Intravenous Therapy Industry is fragmented into hospitals, ambulatory surgical centers, and clinics. The hospital segment held the highest market share, owing to an increase in the number of surgeries performed compared to ambulatory surgical centers and clinics.

By Region Segment Review

[REGIONGRAPH]

Region-wise, the IV therapy & vein access market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America was the highest Intravenous Therapy and Vein Access Market share in 2020, owing to an increase in the pool of patient population, a rise in prevalence of road accidents, the surge in trauma cases, and an increase in government investments in the development of better healthcare facilities and R&D activities.

The key players operating in the global IV therapy & vein access market include Becton, Dickinson & Company, Braun Melsungen AG, Terumo medical corporation, Teleflex Medical Inc., Medtronic Inc., Angiodynamic, Inc.., Smith& Nephew Plc., Pfizer Inc., Insulet Corporation, and Fresenius SE& CO. KGAA.

The other players (the profiles of these players are not covered in the report) in the value chain include Baxter International Inc., iRadimed Corporation, BioScrip, Inc., Grifols, S.A., JW Life Science Co. Ltd., BRIEF-Sichuan Kelun Pharmaceutical Co. Ltd., CVS Health Corporation, and Vifor Pharma Group.

Get more information on this report : Request Sample Pages

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the intravenous (iv) therapy and vein access market analysis from 2020 to 2030 to identify the prevailing intravenous (iv) therapy and vein access market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the intravenous (iv) therapy and vein access market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global intravenous (iv) therapy and vein access market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

  • By Type
    • Implantable Ports
    • Intravenous Catheters
    • Hypodermic Needles
    • Infusion Pumps
    • Other
  • By Medical Application
    • Nutrition And Buffer Solution
    • Volume Expander
    • Medication Administration
    • Blood Based Products
  • By End User
    • Hospitals
    • Ambulatory Surgical Center
    • Clinics
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • U.K.
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • Australia
      • India
      • South Korea
      • Rest Of Asia Pacific
    • LAMEA
      • Brazil
      • South Africa,
      • Saudi Arabia
      • Rest of LAMEA


Key Market Players

  • terumo corporation
  • Medtronic Inc
  • Fresenius SE and Co. KGaA.
  • smiths medical
  • AngioDynamics, Inc.
  • Pfizer Inc
  • Teleflex
  • Baxter international plc
  • B. Braun Melunsung
  • Cardinal Health Inc.
  • CHAPTER 1:INTRODUCTION

    • 1.1.Report description

    • 1.2.Key market segments

    • 1.3.Key benefits to the stakeholders

    • 1.4.Research Methodology

      • 1.4.1.Secondary research

      • 1.4.2.Primary research

      • 1.4.3.Analyst tools and models

  • CHAPTER 2:EXECUTIVE SUMMARY

    • 2.1.Key findings of the study

    • 2.2.CXO Perspective

  • CHAPTER 3:MARKET OVERVIEW

    • 3.1.Market definition and scope

    • 3.2.Key findings

      • 3.2.1.Top investment pockets

    • 3.3.Porter’s five forces analysis

    • 3.4.Top player positioning

    • 3.5.Market dynamics

      • 3.5.1.Drivers

      • 3.5.2.Restraints

      • 3.5.3.Opportunities

    • 3.6.COVID-19 Impact Analysis on the market

  • CHAPTER 4: INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY TYPE

    • 4.1 Overview

      • 4.1.1 Market size and forecast

    • 4.2 Implantable Ports

      • 4.2.1 Key market trends, growth factors and opportunities

      • 4.2.2 Market size and forecast, by region

      • 4.2.3 Market analysis by country

    • 4.3 Intravenous Catheters

      • 4.3.1 Key market trends, growth factors and opportunities

      • 4.3.2 Market size and forecast, by region

      • 4.3.3 Market analysis by country

    • 4.4 Hypodermic Needles

      • 4.4.1 Key market trends, growth factors and opportunities

      • 4.4.2 Market size and forecast, by region

      • 4.4.3 Market analysis by country

    • 4.5 Infusion Pumps

      • 4.5.1 Key market trends, growth factors and opportunities

      • 4.5.2 Market size and forecast, by region

      • 4.5.3 Market analysis by country

    • 4.6 Other

      • 4.6.1 Key market trends, growth factors and opportunities

      • 4.6.2 Market size and forecast, by region

      • 4.6.3 Market analysis by country

  • CHAPTER 5: INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY MEDICAL APPLICATION

    • 5.1 Overview

      • 5.1.1 Market size and forecast

    • 5.2 Volume Expander

      • 5.2.1 Key market trends, growth factors and opportunities

      • 5.2.2 Market size and forecast, by region

      • 5.2.3 Market analysis by country

    • 5.3 Medication Administration

      • 5.3.1 Key market trends, growth factors and opportunities

      • 5.3.2 Market size and forecast, by region

      • 5.3.3 Market analysis by country

    • 5.4 Blood Based Products

      • 5.4.1 Key market trends, growth factors and opportunities

      • 5.4.2 Market size and forecast, by region

      • 5.4.3 Market analysis by country

    • 5.5 Nutrition And Buffer Solution

      • 5.5.1 Key market trends, growth factors and opportunities

      • 5.5.2 Market size and forecast, by region

      • 5.5.3 Market analysis by country

  • CHAPTER 6: INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY END USER

    • 6.1 Overview

      • 6.1.1 Market size and forecast

    • 6.2 Hospitals

      • 6.2.1 Key market trends, growth factors and opportunities

      • 6.2.2 Market size and forecast, by region

      • 6.2.3 Market analysis by country

    • 6.3 Ambulatory Surgical Center

      • 6.3.1 Key market trends, growth factors and opportunities

      • 6.3.2 Market size and forecast, by region

      • 6.3.3 Market analysis by country

    • 6.4 Clinics

      • 6.4.1 Key market trends, growth factors and opportunities

      • 6.4.2 Market size and forecast, by region

      • 6.4.3 Market analysis by country

  • CHAPTER 7: INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY REGION

    • 7.1 Overview

      • 7.1.1 Market size and forecast

    • 7.2 North America

      • 7.2.1 Key trends and opportunities

      • 7.2.2 North America Market size and forecast, by Type

      • 7.2.3 North America Market size and forecast, by Medical Application

      • 7.2.4 North America Market size and forecast, by End User

      • 7.2.5 North America Market size and forecast, by country

        • 7.2.5.1 U.S.
          • 7.2.5.1.1 Market size and forecast, by Type
          • 7.2.5.1.2 Market size and forecast, by Medical Application
          • 7.2.5.1.3 Market size and forecast, by End User
        • 7.2.5.2 Canada
          • 7.2.5.2.1 Market size and forecast, by Type
          • 7.2.5.2.2 Market size and forecast, by Medical Application
          • 7.2.5.2.3 Market size and forecast, by End User
        • 7.2.5.3 Mexico
          • 7.2.5.3.1 Market size and forecast, by Type
          • 7.2.5.3.2 Market size and forecast, by Medical Application
          • 7.2.5.3.3 Market size and forecast, by End User
    • 7.3 Europe

      • 7.3.1 Key trends and opportunities

      • 7.3.2 Europe Market size and forecast, by Type

      • 7.3.3 Europe Market size and forecast, by Medical Application

      • 7.3.4 Europe Market size and forecast, by End User

      • 7.3.5 Europe Market size and forecast, by country

        • 7.3.5.1 Germany
          • 7.3.5.1.1 Market size and forecast, by Type
          • 7.3.5.1.2 Market size and forecast, by Medical Application
          • 7.3.5.1.3 Market size and forecast, by End User
        • 7.3.5.2 France
          • 7.3.5.2.1 Market size and forecast, by Type
          • 7.3.5.2.2 Market size and forecast, by Medical Application
          • 7.3.5.2.3 Market size and forecast, by End User
        • 7.3.5.3 U.K.
          • 7.3.5.3.1 Market size and forecast, by Type
          • 7.3.5.3.2 Market size and forecast, by Medical Application
          • 7.3.5.3.3 Market size and forecast, by End User
        • 7.3.5.4 Italy
          • 7.3.5.4.1 Market size and forecast, by Type
          • 7.3.5.4.2 Market size and forecast, by Medical Application
          • 7.3.5.4.3 Market size and forecast, by End User
        • 7.3.5.5 Spain
          • 7.3.5.5.1 Market size and forecast, by Type
          • 7.3.5.5.2 Market size and forecast, by Medical Application
          • 7.3.5.5.3 Market size and forecast, by End User
        • 7.3.5.6 Rest of Europe
          • 7.3.5.6.1 Market size and forecast, by Type
          • 7.3.5.6.2 Market size and forecast, by Medical Application
          • 7.3.5.6.3 Market size and forecast, by End User
    • 7.4 Asia-Pacific

      • 7.4.1 Key trends and opportunities

      • 7.4.2 Asia-Pacific Market size and forecast, by Type

      • 7.4.3 Asia-Pacific Market size and forecast, by Medical Application

      • 7.4.4 Asia-Pacific Market size and forecast, by End User

      • 7.4.5 Asia-Pacific Market size and forecast, by country

        • 7.4.5.1 Japan
          • 7.4.5.1.1 Market size and forecast, by Type
          • 7.4.5.1.2 Market size and forecast, by Medical Application
          • 7.4.5.1.3 Market size and forecast, by End User
        • 7.4.5.2 China
          • 7.4.5.2.1 Market size and forecast, by Type
          • 7.4.5.2.2 Market size and forecast, by Medical Application
          • 7.4.5.2.3 Market size and forecast, by End User
        • 7.4.5.3 Australia
          • 7.4.5.3.1 Market size and forecast, by Type
          • 7.4.5.3.2 Market size and forecast, by Medical Application
          • 7.4.5.3.3 Market size and forecast, by End User
        • 7.4.5.4 India
          • 7.4.5.4.1 Market size and forecast, by Type
          • 7.4.5.4.2 Market size and forecast, by Medical Application
          • 7.4.5.4.3 Market size and forecast, by End User
        • 7.4.5.5 South Korea
          • 7.4.5.5.1 Market size and forecast, by Type
          • 7.4.5.5.2 Market size and forecast, by Medical Application
          • 7.4.5.5.3 Market size and forecast, by End User
        • 7.4.5.6 Rest Of Asia Pacific
          • 7.4.5.6.1 Market size and forecast, by Type
          • 7.4.5.6.2 Market size and forecast, by Medical Application
          • 7.4.5.6.3 Market size and forecast, by End User
    • 7.5 LAMEA

      • 7.5.1 Key trends and opportunities

      • 7.5.2 LAMEA Market size and forecast, by Type

      • 7.5.3 LAMEA Market size and forecast, by Medical Application

      • 7.5.4 LAMEA Market size and forecast, by End User

      • 7.5.5 LAMEA Market size and forecast, by country

        • 7.5.5.1 Brazil
          • 7.5.5.1.1 Market size and forecast, by Type
          • 7.5.5.1.2 Market size and forecast, by Medical Application
          • 7.5.5.1.3 Market size and forecast, by End User
        • 7.5.5.2 South Africa,
          • 7.5.5.2.1 Market size and forecast, by Type
          • 7.5.5.2.2 Market size and forecast, by Medical Application
          • 7.5.5.2.3 Market size and forecast, by End User
        • 7.5.5.3 Saudi Arabia
          • 7.5.5.3.1 Market size and forecast, by Type
          • 7.5.5.3.2 Market size and forecast, by Medical Application
          • 7.5.5.3.3 Market size and forecast, by End User
        • 7.5.5.4 Rest of LAMEA
          • 7.5.5.4.1 Market size and forecast, by Type
          • 7.5.5.4.2 Market size and forecast, by Medical Application
          • 7.5.5.4.3 Market size and forecast, by End User
  • CHAPTER 8: COMPANY LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top winning strategies

    • 8.3. Product Mapping of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Key developments

  • CHAPTER 9: COMPANY PROFILES

    • 9.1 Medtronic Inc

      • 9.1.1 Company overview

      • 9.1.2 Company snapshot

      • 9.1.3 Operating business segments

      • 9.1.4 Product portfolio

      • 9.1.5 Business performance

      • 9.1.6 Key strategic moves and developments

    • 9.2 Teleflex

      • 9.2.1 Company overview

      • 9.2.2 Company snapshot

      • 9.2.3 Operating business segments

      • 9.2.4 Product portfolio

      • 9.2.5 Business performance

      • 9.2.6 Key strategic moves and developments

    • 9.3 B. Braun Melunsung

      • 9.3.1 Company overview

      • 9.3.2 Company snapshot

      • 9.3.3 Operating business segments

      • 9.3.4 Product portfolio

      • 9.3.5 Business performance

      • 9.3.6 Key strategic moves and developments

    • 9.4 terumo corporation

      • 9.4.1 Company overview

      • 9.4.2 Company snapshot

      • 9.4.3 Operating business segments

      • 9.4.4 Product portfolio

      • 9.4.5 Business performance

      • 9.4.6 Key strategic moves and developments

    • 9.5 AngioDynamics, Inc.

      • 9.5.1 Company overview

      • 9.5.2 Company snapshot

      • 9.5.3 Operating business segments

      • 9.5.4 Product portfolio

      • 9.5.5 Business performance

      • 9.5.6 Key strategic moves and developments

    • 9.6 Fresenius SE and Co. KGaA.

      • 9.6.1 Company overview

      • 9.6.2 Company snapshot

      • 9.6.3 Operating business segments

      • 9.6.4 Product portfolio

      • 9.6.5 Business performance

      • 9.6.6 Key strategic moves and developments

    • 9.7 Baxter international plc

      • 9.7.1 Company overview

      • 9.7.2 Company snapshot

      • 9.7.3 Operating business segments

      • 9.7.4 Product portfolio

      • 9.7.5 Business performance

      • 9.7.6 Key strategic moves and developments

    • 9.8 Pfizer Inc

      • 9.8.1 Company overview

      • 9.8.2 Company snapshot

      • 9.8.3 Operating business segments

      • 9.8.4 Product portfolio

      • 9.8.5 Business performance

      • 9.8.6 Key strategic moves and developments

    • 9.9 Cardinal Health Inc.

      • 9.9.1 Company overview

      • 9.9.2 Company snapshot

      • 9.9.3 Operating business segments

      • 9.9.4 Product portfolio

      • 9.9.5 Business performance

      • 9.9.6 Key strategic moves and developments

    • 9.10 smiths medical

      • 9.10.1 Company overview

      • 9.10.2 Company snapshot

      • 9.10.3 Operating business segments

      • 9.10.4 Product portfolio

      • 9.10.5 Business performance

      • 9.10.6 Key strategic moves and developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY TYPE, 2020-2030,($MILLION)
    TABLE 2. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR IMPLANTABLE PORTS, BY REGION , 2020-2030,($MILLION)
    TABLE 3. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET IMPLANTABLE PORTS BY COUNTRY, 2020-2030,($MILLION)
    TABLE 4. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR INTRAVENOUS CATHETERS, BY REGION , 2020-2030,($MILLION)
    TABLE 5. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET INTRAVENOUS CATHETERS BY COUNTRY, 2020-2030,($MILLION)
    TABLE 6. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR HYPODERMIC NEEDLES, BY REGION , 2020-2030,($MILLION)
    TABLE 7. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET HYPODERMIC NEEDLES BY COUNTRY, 2020-2030,($MILLION)
    TABLE 8. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR INFUSION PUMPS, BY REGION , 2020-2030,($MILLION)
    TABLE 9. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET INFUSION PUMPS BY COUNTRY, 2020-2030,($MILLION)
    TABLE 10. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR OTHER, BY REGION , 2020-2030,($MILLION)
    TABLE 11. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET OTHER BY COUNTRY, 2020-2030,($MILLION)
    TABLE 12. GLOBAL INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY MEDICAL APPLICATION, 2020-2030,($MILLION)
    TABLE 13. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR VOLUME EXPANDER, BY REGION , 2020-2030,($MILLION)
    TABLE 14. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET VOLUME EXPANDER BY COUNTRY, 2020-2030,($MILLION)
    TABLE 15. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR MEDICATION ADMINISTRATION, BY REGION , 2020-2030,($MILLION)
    TABLE 16. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET MEDICATION ADMINISTRATION BY COUNTRY, 2020-2030,($MILLION)
    TABLE 17. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR BLOOD BASED PRODUCTS, BY REGION , 2020-2030,($MILLION)
    TABLE 18. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BLOOD BASED PRODUCTS BY COUNTRY, 2020-2030,($MILLION)
    TABLE 19. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR NUTRITION AND BUFFER SOLUTION, BY REGION , 2020-2030,($MILLION)
    TABLE 20. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET NUTRITION AND BUFFER SOLUTION BY COUNTRY, 2020-2030,($MILLION)
    TABLE 21. GLOBAL INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY END USER, 2020-2030,($MILLION)
    TABLE 22. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR HOSPITALS, BY REGION , 2020-2030,($MILLION)
    TABLE 23. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET HOSPITALS BY COUNTRY, 2020-2030,($MILLION)
    TABLE 24. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR AMBULATORY SURGICAL CENTER, BY REGION , 2020-2030,($MILLION)
    TABLE 25. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET AMBULATORY SURGICAL CENTER BY COUNTRY, 2020-2030,($MILLION)
    TABLE 26. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR CLINICS, BY REGION , 2020-2030,($MILLION)
    TABLE 27. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET CLINICS BY COUNTRY, 2020-2030,($MILLION)
    TABLE 28. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY REGION, 2020-2030,($MILLION)
    TABLE 29. NORTH AMERICA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY TYPE, 2020-2030,($MILLION)
    TABLE 30. NORTH AMERICA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY MEDICAL APPLICATION, 2020-2030,($MILLION)
    TABLE 31. NORTH AMERICA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY END USER, 2020-2030,($MILLION)
    TABLE 32. NORTH AMERICA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY COUNTRY, 2020-2030,($MILLION)
    TABLE 33. U.S. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION)
    TABLE 34. U.S. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION)
    TABLE 35. U.S. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION)
    TABLE 36. CANADA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION)
    TABLE 37. CANADA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION)
    TABLE 38. CANADA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION)
    TABLE 39. MEXICO INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION)
    TABLE 40. MEXICO INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION)
    TABLE 41. MEXICO INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION)
    TABLE 42. EUROPE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY TYPE, 2020-2030,($MILLION)
    TABLE 43. EUROPE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY MEDICAL APPLICATION, 2020-2030,($MILLION)
    TABLE 44. EUROPE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY END USER, 2020-2030,($MILLION)
    TABLE 45. EUROPE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY COUNTRY, 2020-2030,($MILLION)
    TABLE 46. GERMANY INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION)
    TABLE 47. GERMANY INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION)
    TABLE 48. GERMANY INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION)
    TABLE 49. FRANCE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION)
    TABLE 50. FRANCE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION)
    TABLE 51. FRANCE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION)
    TABLE 52. U.K. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION)
    TABLE 53. U.K. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION)
    TABLE 54. U.K. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION)
    TABLE 55. ITALY INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION)
    TABLE 56. ITALY INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION)
    TABLE 57. ITALY INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION)
    TABLE 58. SPAIN INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION)
    TABLE 59. SPAIN INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION)
    TABLE 60. SPAIN INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION)
    TABLE 61. REST OF EUROPE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION)
    TABLE 62. REST OF EUROPE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION)
    TABLE 63. REST OF EUROPE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION)
    TABLE 64. ASIA-PACIFIC INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY TYPE, 2020-2030,($MILLION)
    TABLE 65. ASIA-PACIFIC INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY MEDICAL APPLICATION, 2020-2030,($MILLION)
    TABLE 66. ASIA-PACIFIC INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY END USER, 2020-2030,($MILLION)
    TABLE 67. ASIA-PACIFIC INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY COUNTRY, 2020-2030,($MILLION)
    TABLE 68. JAPAN INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION)
    TABLE 69. JAPAN INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION)
    TABLE 70. JAPAN INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION)
    TABLE 71. CHINA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION)
    TABLE 72. CHINA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION)
    TABLE 73. CHINA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION)
    TABLE 74. AUSTRALIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION)
    TABLE 75. AUSTRALIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION)
    TABLE 76. AUSTRALIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION)
    TABLE 77. INDIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION)
    TABLE 78. INDIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION)
    TABLE 79. INDIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION)
    TABLE 80. SOUTH KOREA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION)
    TABLE 81. SOUTH KOREA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION)
    TABLE 82. SOUTH KOREA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION)
    TABLE 83. REST OF ASIA PACIFIC INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION)
    TABLE 84. REST OF ASIA PACIFIC INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION)
    TABLE 85. REST OF ASIA PACIFIC INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION)
    TABLE 86. LAMEA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY TYPE, 2020-2030,($MILLION)
    TABLE 87. LAMEA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY MEDICAL APPLICATION, 2020-2030,($MILLION)
    TABLE 88. LAMEA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY END USER, 2020-2030,($MILLION)
    TABLE 89. LAMEA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY COUNTRY, 2020-2030,($MILLION)
    TABLE 90. BRAZIL INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION)
    TABLE 91. BRAZIL INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION)
    TABLE 92. BRAZIL INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION)
    TABLE 93. SOUTH AFRICA, INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION)
    TABLE 94. SOUTH AFRICA, INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION)
    TABLE 95. SOUTH AFRICA, INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION)
    TABLE 96. SAUDI ARABIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION)
    TABLE 97. SAUDI ARABIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION)
    TABLE 98. SAUDI ARABIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION)
    TABLE 99. REST OF LAMEA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION)
    TABLE 100. REST OF LAMEA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION)
    TABLE 101. REST OF LAMEA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION)
    TABLE 102.MEDTRONIC INC: COMPANY SNAPSHOT
    TABLE 103.MEDTRONIC INC: OPERATING SEGMENTS
    TABLE 104.MEDTRONIC INC: PRODUCT PORTFOLIO
    TABLE 105.MEDTRONIC INC: NET SALES,
    TABLE 106.MEDTRONIC INC: KEY STRATERGIES
    TABLE 107.TELEFLEX: COMPANY SNAPSHOT
    TABLE 108.TELEFLEX: OPERATING SEGMENTS
    TABLE 109.TELEFLEX: PRODUCT PORTFOLIO
    TABLE 110.TELEFLEX: NET SALES,
    TABLE 111.TELEFLEX: KEY STRATERGIES
    TABLE 112.B. BRAUN MELUNSUNG: COMPANY SNAPSHOT
    TABLE 113.B. BRAUN MELUNSUNG: OPERATING SEGMENTS
    TABLE 114.B. BRAUN MELUNSUNG: PRODUCT PORTFOLIO
    TABLE 115.B. BRAUN MELUNSUNG: NET SALES,
    TABLE 116.B. BRAUN MELUNSUNG: KEY STRATERGIES
    TABLE 117.TERUMO CORPORATION: COMPANY SNAPSHOT
    TABLE 118.TERUMO CORPORATION: OPERATING SEGMENTS
    TABLE 119.TERUMO CORPORATION: PRODUCT PORTFOLIO
    TABLE 120.TERUMO CORPORATION: NET SALES,
    TABLE 121.TERUMO CORPORATION: KEY STRATERGIES
    TABLE 122.ANGIODYNAMICS, INC.: COMPANY SNAPSHOT
    TABLE 123.ANGIODYNAMICS, INC.: OPERATING SEGMENTS
    TABLE 124.ANGIODYNAMICS, INC.: PRODUCT PORTFOLIO
    TABLE 125.ANGIODYNAMICS, INC.: NET SALES,
    TABLE 126.ANGIODYNAMICS, INC.: KEY STRATERGIES
    TABLE 127.FRESENIUS SE AND CO. KGAA.: COMPANY SNAPSHOT
    TABLE 128.FRESENIUS SE AND CO. KGAA.: OPERATING SEGMENTS
    TABLE 129.FRESENIUS SE AND CO. KGAA.: PRODUCT PORTFOLIO
    TABLE 130.FRESENIUS SE AND CO. KGAA.: NET SALES,
    TABLE 131.FRESENIUS SE AND CO. KGAA.: KEY STRATERGIES
    TABLE 132.BAXTER INTERNATIONAL PLC: COMPANY SNAPSHOT
    TABLE 133.BAXTER INTERNATIONAL PLC: OPERATING SEGMENTS
    TABLE 134.BAXTER INTERNATIONAL PLC: PRODUCT PORTFOLIO
    TABLE 135.BAXTER INTERNATIONAL PLC: NET SALES,
    TABLE 136.BAXTER INTERNATIONAL PLC: KEY STRATERGIES
    TABLE 137.PFIZER INC: COMPANY SNAPSHOT
    TABLE 138.PFIZER INC: OPERATING SEGMENTS
    TABLE 139.PFIZER INC: PRODUCT PORTFOLIO
    TABLE 140.PFIZER INC: NET SALES,
    TABLE 141.PFIZER INC: KEY STRATERGIES
    TABLE 142.CARDINAL HEALTH INC.: COMPANY SNAPSHOT
    TABLE 143.CARDINAL HEALTH INC.: OPERATING SEGMENTS
    TABLE 144.CARDINAL HEALTH INC.: PRODUCT PORTFOLIO
    TABLE 145.CARDINAL HEALTH INC.: NET SALES,
    TABLE 146.CARDINAL HEALTH INC.: KEY STRATERGIES
    TABLE 147.SMITHS MEDICAL: COMPANY SNAPSHOT
    TABLE 148.SMITHS MEDICAL: OPERATING SEGMENTS
    TABLE 149.SMITHS MEDICAL: PRODUCT PORTFOLIO
    TABLE 150.SMITHS MEDICAL: NET SALES,
    TABLE 151.SMITHS MEDICAL: KEY STRATERGIES
  • LIST OF FIGURES

  • FIGURE 1.INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET SEGMENTATION
    FIGURE 2.INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030
    FIGURE 3.INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030
    FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
    FIGURE 5.PORTER FIVE-1
    FIGURE 6.PORTER FIVE-2
    FIGURE 7.PORTER FIVE-3
    FIGURE 8.PORTER FIVE-4
    FIGURE 9.PORTER FIVE-5
    FIGURE 10.TOP PLAYER POSITIONING
    FIGURE 11.INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
    FIGURE 11.INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,BY TYPE,2020(%)
    FIGURE 12.COMPARATIVE SHARE ANALYSIS OF IMPLANTABLE PORTS INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%)
    FIGURE 13.COMPARATIVE SHARE ANALYSIS OF INTRAVENOUS CATHETERS INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%)
    FIGURE 14.COMPARATIVE SHARE ANALYSIS OF HYPODERMIC NEEDLES INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%)
    FIGURE 15.COMPARATIVE SHARE ANALYSIS OF INFUSION PUMPS INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%)
    FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OTHER INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%)
    FIGURE 17.INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,BY MEDICAL APPLICATION,2020(%)
    FIGURE 18.COMPARATIVE SHARE ANALYSIS OF VOLUME EXPANDER INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%)
    FIGURE 19.COMPARATIVE SHARE ANALYSIS OF MEDICATION ADMINISTRATION INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%)
    FIGURE 20.COMPARATIVE SHARE ANALYSIS OF BLOOD BASED PRODUCTS INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%)
    FIGURE 21.COMPARATIVE SHARE ANALYSIS OF NUTRITION AND BUFFER SOLUTION INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%)
    FIGURE 22.INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,BY END USER,2020(%)
    FIGURE 23.COMPARATIVE SHARE ANALYSIS OF HOSPITALS INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%)
    FIGURE 24.COMPARATIVE SHARE ANALYSIS OF AMBULATORY SURGICAL CENTER INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%)
    FIGURE 25.COMPARATIVE SHARE ANALYSIS OF CLINICS INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%)
    FIGURE 26.INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY REGION,2020
    FIGURE 27.U.S. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION)
    FIGURE 28.CANADA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION)
    FIGURE 29.MEXICO INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION)
    FIGURE 30.GERMANY INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION)
    FIGURE 31.FRANCE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION)
    FIGURE 32.U.K. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION)
    FIGURE 33.ITALY INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION)
    FIGURE 34.SPAIN INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION)
    FIGURE 35.REST OF EUROPE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION)
    FIGURE 36.JAPAN INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION)
    FIGURE 37.CHINA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION)
    FIGURE 38.AUSTRALIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION)
    FIGURE 39.INDIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION)
    FIGURE 40.SOUTH KOREA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION)
    FIGURE 41.REST OF ASIA PACIFIC INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION)
    FIGURE 42.BRAZIL INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION)
    FIGURE 43.SOUTH AFRICA, INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION)
    FIGURE 44.SAUDI ARABIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION)
    FIGURE 45.REST OF LAMEA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION)
    FIGURE 46. TOP WINNING STRATEGIES, BY YEAR
    FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT
    FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY
    FIGURE 49.PRODUCT MAPPING OF TOP 10 PLAYERS
    FIGURE 50.COMPETITIVE DASHBOARD
    FIGURE 51.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
    FIGURE 52.MEDTRONIC INC.: NET SALES ,($MILLION)
    FIGURE 53.TELEFLEX.: NET SALES ,($MILLION)
    FIGURE 54.B. BRAUN MELUNSUNG.: NET SALES ,($MILLION)
    FIGURE 55.TERUMO CORPORATION.: NET SALES ,($MILLION)
    FIGURE 56.ANGIODYNAMICS, INC..: NET SALES ,($MILLION)
    FIGURE 57.FRESENIUS SE AND CO. KGAA..: NET SALES ,($MILLION)
    FIGURE 58.BAXTER INTERNATIONAL PLC.: NET SALES ,($MILLION)
    FIGURE 59.PFIZER INC.: NET SALES ,($MILLION)
    FIGURE 60.CARDINAL HEALTH INC..: NET SALES ,($MILLION)
    FIGURE 61.SMITHS MEDICAL.: NET SALES ,($MILLION)

Purchase Full Report of
Intravenous (IV) Therapy and Vein Access Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue